Amedeo Smart

Free Medical Literature Service



Liver Diseases

  Free Subscription

Articles published in
J Clin Oncol
    June 2024
  1. ETTRICH TJ, Modest DP, Sinn M, Striefler JK, et al
    Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).
    J Clin Oncol. 2024 Jun 6:JCO2301566. doi: 10.1200/JCO.23.01566.
    >> Share

    May 2024
  2. SANGRO B, Galle PR, Kelley RK, Charoentum C, et al
    Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    J Clin Oncol. 2024 May 28:JCO2301462. doi: 10.1200/JCO.23.01462.
    >> Share

  3. FICHTINGER RS, Aldrighetti LA, Abu Hilal M, Troisi RI, et al
    Laparoscopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1799-1809.
    >> Share

    April 2024
  4. CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al
    Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases.
    J Clin Oncol. 2024;42:1098-1101.
    >> Share

    March 2024
  5. GORDAN JD, Kennedy EB, Abou-Alfa GK, Beal E, et al
    Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
    J Clin Oncol. 2024 Mar 19:JCO2302745. doi: 10.1200/JCO.23.02745.
    >> Share

    January 2024
  6. HUANG DQ, Hoang JK, Kamal R, Tsai PC, et al
    Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.
    J Clin Oncol. 2024 Jan 4:JCO2300757. doi: 10.1200/JCO.23.00757.
    >> Share

    November 2023
  7. WANG G, Zhuo N, Liu Z
    Nonalcoholic Fatty Liver Disease May Be an Independent, Modifiable Risk Factor for Young-Onset Digestive Tract Cancers.
    J Clin Oncol. 2023;41:5070.
    >> Share

    June 2023
  8. OOSTEROM N, Gooskens SLM, Renfro LA, Perlman EJ, et al
    Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy.
    J Clin Oncol. 2023 Jun 21:JCO2202555. doi: 10.1200/JCO.22.02555.
    >> Share

  9. PARK JH, Hong JY, Shen JJ, Han K, et al
    Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study.
    J Clin Oncol. 2023;41:3363-3373.
    >> Share

    Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer.
    J Clin Oncol. 2023 Jun 15:JCO2300460. doi: 10.1200/JCO.23.00460.
    >> Share

  11. LURAIN K
    Treating Cancer in People With HIV.
    J Clin Oncol. 2023 Jun 2:JCO2300737. doi: 10.1200/JCO.23.00737.
    >> Share

    May 2023
  12. EL ZARIF T, Nassar AH, Adib E, Fitzgerald BG, et al
    Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
    J Clin Oncol. 2023 May 16:JCO2202459. doi: 10.1200/JCO.22.02459.
    >> Share

    April 2023
  13. LIN TA, Das A, McCaw Z, Ludmir EB, et al
    Determining the Efficacy of Pembrolizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma.
    J Clin Oncol. 2023 Apr 4:JCO2300072. doi: 10.1200/JCO.23.00072.
    >> Share

    March 2023
  14. SANDHYA L, Devi Sreenivasan N, Goenka L, Dubashi B, et al
    Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.
    J Clin Oncol. 2023 Mar 28:JCO2201997. doi: 10.1200/JCO.22.01997.
    >> Share

  15. OLOFSSON BAGGE R, Nelson A, Shafazand A, All-Eriksson C, et al
    Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).
    J Clin Oncol. 2023 Mar 20:JCO2201705. doi: 10.1200/JCO.22.01705.
    >> Share

    December 2022
  16. LI SH, Mei J, Cheng Y, Li Q, et al
    Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
    J Clin Oncol. 2022 Dec 16:JCO2201142. doi: 10.1200/JCO.22.01142.
    >> Share

  17. YAU T, Zagonel V, Santoro A, Acosta-Rivera M, et al
    Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
    J Clin Oncol. 2022 Dec 13:JCO2200972. doi: 10.1200/JCO.22.00972.
    >> Share

  18. QIN S, Chen Z, Fang W, Ren Z, et al
    Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.
    J Clin Oncol. 2022 Dec 1:JCO2200620. doi: 10.1200/JCO.22.00620.
    >> Share

    August 2022
  19. PENG Z, Fan W, Zhu B, Wang G, et al
    Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
    J Clin Oncol. 2022 Aug 3:JCO2200392. doi: 10.1200/JCO.22.00392.
    >> Share

    June 2022
  20. BEJJANI AC, Finn RS
    Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations.
    J Clin Oncol. 2022 Jun 1:JCO2102605. doi: 10.1200/JCO.21.02605.
    >> Share

  21. RAPHAEL MJ, Karanicolas PJ
    Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?
    J Clin Oncol. 2022 Jun 1:JCO2102505. doi: 10.1200/JCO.21.02505.
    >> Share

    May 2022
  22. CHIANG CH, Chiang CH, Chiang CH
    Are H1-Antihistamines Associated With a Lower Risk of Hepatocellular Carcinoma?
    J Clin Oncol. 2022 May 12:JCO2200179. doi: 10.1200/JCO.22.00179.
    >> Share

    March 2022
  23. SUTCUOGLU O, Ulas Kahya B, Ozdemir N, Yazici O, et al
    Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
    J Clin Oncol. 2022 Mar 29:JCO2200047. doi: 10.1200/JCO.22.00047.
    >> Share

  24. JOHNSON PJ, Pinato DJ, Kalyuzhnyy A, Toyoda H, et al
    Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.
    J Clin Oncol. 2022 Mar 28:JCO2102373. doi: 10.1200/JCO.21.02373.
    >> Share

  25. MEI J, Yu H, Qin L, Jia Z, et al
    FOLFOX-HAIC for Unresectable Large Hepatocellular Carcinoma: The Effectiveness Has Yet to be Determined.
    J Clin Oncol. 2022 Mar 22:JCO2102533. doi: 10.1200/JCO.21.02533.
    >> Share

    January 2022
  26. SHEN YC, Hsu HC, Lin TM, Chang YS, et al
    H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection.
    J Clin Oncol. 2022 Jan 19:JCO2101802. doi: 10.1200/JCO.21.01802.
    >> Share

    December 2021
  27. LYU N, Wang X, Li JB, Lai JF, et al
    Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    J Clin Oncol. 2021 Dec 14:JCO2101963. doi: 10.1200/JCO.21.01963.
    >> Share

  28. MULCAHY MF, Mahvash A, Pracht M, Montazeri AH, et al
    Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
    J Clin Oncol. 2021;39:3897-3907.
    >> Share

  29. TROBAUGH-LOTRARIO A, Katzenstein HM, Ranganathan S, Lopez-Terrada D, et al
    Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee.
    J Clin Oncol. 2021 Dec 7:JCO2100803. doi: 10.1200/JCO.21.00803.
    >> Share

  30. SALEM R
    Hepatic Arterial Infusion Chemotherapy for Large Hepatocellular Carcinoma: Ready for Prime Time?
    J Clin Oncol. 2021 Dec 2:JCO2102392. doi: 10.1200/JCO.21.02392.
    >> Share

    October 2021
  31. LI QJ, He MK, Chen HW, Fang WQ, et al
    Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    J Clin Oncol. 2021 Oct 14:JCO2100608. doi: 10.1200/JCO.21.00608.
    >> Share

    September 2021
  32. BOOTH CM, Berry SR
    Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot?
    J Clin Oncol. 2021 Sep 24:JCO2101972. doi: 10.1200/JCO.21.01972.
    >> Share

  33. LENTZ RW, Messersmith WA
    Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases.
    J Clin Oncol. 2021 Sep 20:JCO2101993. doi: 10.1200/JCO.21.01993.
    >> Share

  34. KANEMITSU Y, Shimizu Y, Mizusawa J, Inaba Y, et al
    Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial.
    J Clin Oncol. 2021 Sep 14:JCO2101032. doi: 10.1200/JCO.21.01032.
    >> Share

  35. RAYSON D
    J Clin Oncol. 2021;39:2962-2963.
    >> Share

    July 2021
  36. KELLEY RK, Sangro B, Harris W, Ikeda M, et al
    Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    J Clin Oncol. 2021 Jul 22:JCO2003555. doi: 10.1200/JCO.20.03555.
    >> Share

    June 2021
  37. QIN S, Bi F, Gu S, Bai Y, et al
    Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
    J Clin Oncol. 2021 Jun 29:JCO2100163. doi: 10.1200/JCO.21.00163.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016